Osimertinib Resistance and EGFR Mutations in NSCLC Treatment
The presence of the T790M mutation during first or second-generation EGFR-TKI treatments is observed in 50-60% of patients. This mutation ...
Tag: EGFR mutations
Advances in NSCLC Treatment – Overcoming Osimertinib Resistance and Exploring the Potential of Amivantamab and Lazertinib
In the ever-evolving landscape of cancer treatment, recent breakthroughs in the fight against non-small cell lung cancer (NSCLC) have brought ...
Fighting Osimertinib Resistance in Lung Cancer Treatment
Lung cancer remains one of the leading causes of cancer-related deaths worldwide. Among its types, non-small cell lung cancer (NSCLC) ...
Results of the MARIPOSA-2 Study for Advanced Lung Cancer
The latest advancements in cancer treatment are offering new hope to patients with advanced non-small cell lung cancer (NSCLC), especially ...
